Pioneering Progress: The Evolution of Dermatology at Incyte
As we approach this year’s American Academy of Dermatology (AAD) Annual Meeting, we are proud to showcase our investigational pipeline through studies across many disease areas and reflect on the evolution of our work in the field.
Rooted in our heritage and expertise in immunology, the start of our efforts in Dermatology marked the beginning of an exciting new chapter for Incyte. Since then, our research and development teams have been focused on advancing new treatment options for people living with immune-mediated dermatologic conditions.
Exploring the therapeutic potential of key pathways and signaling mechanisms within the body's immune system to identify new ways to target and treat a variety of immune-mediated dermatologic conditions has been at the forefront of our research.
We have never wavered in our pursuit of science and innovation, first in Myeloproliferative Neoplasms and Oncology and now in Dermatology, and as a result, have advanced and made available first-in-class treatments to people living with a variety of conditions, including vitiligo,” says Pablo Cagnoni, President and Head of R&D at Incyte. “Our dedication and investment in research and development drives our ability to innovate and this is just the beginning. I am excited to see where our science will take us next.
In addition to important progress made to introduce new and first-ever treatments for patients living with AD and vitiligo, respectively, we are expanding our efforts to address additional diseases and explore new therapies for other inflammatory skin conditions including:
- Prurigo nodularis (PN): A chronic condition that causes itchy bumps on the skin called “nodules” that appear after excessive scratching. It typically occurs on the arms, legs and trunk of the body.
- Hidradenitis suppurativa (HS): Also known as acne inversa, HS is a difficult to treat condition that causes red, painful bumps typically in the armpits and groin.
- Lichen planus: A chronic disorder that causes itchy and purple bumps or plaques on the skin that may also present on the nails and in the mouth.
It has been truly remarkable to witness the progress of our clinical programs in Dermatology and our expanding research across disease states,” says Jim Lee, Group Vice President, Head, Inflammation and Autoimmunity at Incyte. “We are entering a new era in Dermatology research and development and it’s exciting to be part of that.
Every day, our unwavering resolve is to Solve On. for patients living with challenging conditions. Whether in Dermatology or in our other focus areas, including Oncology and Inflammation & Autoimmunity, patients are our greatest motivators.
